Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283690952> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4283690952 endingPage "901" @default.
- W4283690952 startingPage "900.2" @default.
- W4283690952 abstract "Background Animal studies suggest that advanced glycation end-products (AGEs) and their interaction with receptor for AGEs (RAGE) are involved in sarcopenia, but their relationship in human skeletal muscles has yet to be elucidated. Objectives We aimed to determine whether RAGE expression in human skeletal muscle is associated with serum AGE levels and sarcopenia-related changes. Methods We reviewed 33 consecutive women (mean age, 65 years) with distal radius fracture who had consented to donate a sample of forearm flexor muscle for research purposes, which was taken during surgical fracture repair. The muscle RAGE expression was measured with immunohistochemistry staining and serum AGE levels using ELISA method. We compared RAGE expression and AGE levels in patients with and without sarcopenia. We also correlated RAGE expression with such clinical parameters as age, body mass index, bone mineral density (BMD), as well as sarcopenia-related changes, including grip strength, appendicular skeletal muscle mass, and muscle cross-sectional area (CSA) ratios. Results Twelve patients (36%) were diagnosed with sarcopenia according to the Asian Working Group for Sarcopenia. They had a significantly higher RAGE expression ( p = 0.044) and AGE level ( p < 0.001) than those without sarcopenia. The RAGE expression correlated significantly with a high serum AGE level ( r = 0.510, p = 0.011) and correlated inversely with a muscle CSA ratio ( r = -0.696, p < 0.001). Conclusion This study shows that RAGE expression increases in sarcopenic patient skeletal muscles. This expression also correlates positively with serum AGE levels and inversely with muscle CSA ratios. Further studies are necessary to determine whether targeting RAGEs can be a therapeutic option for sarcopenia. References [1]Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001; 44: 129-46. [2]Tabara Y, Ikezoe T, Yamanaka M et al. Advanced glycation end product accumulation is associated with low skeletal mass, weak muscle strength, and reduced bone density: the Nagahama study. J Gerontol A Biol Sci Med Sci. 2019; 74: 1446-53. [3]Riuzzi F, Sorci G, Sagheddu R, Chiappalupi S, Salvadori L, Donato R. RAGE in the pathophysiology of skeletal muscle. J Cachexia Sarcopenia Muscle. 2018; 9: 1213-34. Figure 1. Skeletal muscle tissue (x 7.0) obtained from (a) a 76-year-old female with receptor for advanced glycation end-products (RAGE) expression scoring 14, and (b) a 75-year-old female with RAGE expression scoring 50. Disparity between the percentage of fibers with signal intensity of 1+ (arrow) and those with signal intensity of 2+ (arrowhead) is obvious. Difference in the diameter and homogeneity of the muscle fibers imply the role of RAGE hyperexpression in sarcopenia. Disclosure of Interests None declared" @default.
- W4283690952 created "2022-06-30" @default.
- W4283690952 creator A5020370145 @default.
- W4283690952 creator A5021245873 @default.
- W4283690952 creator A5049682044 @default.
- W4283690952 creator A5061167321 @default.
- W4283690952 date "2022-05-23" @default.
- W4283690952 modified "2023-09-26" @default.
- W4283690952 title "POS1144 INCREASED EXPRESSION OF RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS IN SARCOPENIC PATIENT SKELETAL MUSCLE" @default.
- W4283690952 doi "https://doi.org/10.1136/annrheumdis-2022-eular.1502" @default.
- W4283690952 hasPublicationYear "2022" @default.
- W4283690952 type Work @default.
- W4283690952 citedByCount "0" @default.
- W4283690952 crossrefType "journal-article" @default.
- W4283690952 hasAuthorship W4283690952A5020370145 @default.
- W4283690952 hasAuthorship W4283690952A5021245873 @default.
- W4283690952 hasAuthorship W4283690952A5049682044 @default.
- W4283690952 hasAuthorship W4283690952A5061167321 @default.
- W4283690952 hasBestOaLocation W42836909521 @default.
- W4283690952 hasConcept C126322002 @default.
- W4283690952 hasConcept C134018914 @default.
- W4283690952 hasConcept C141071460 @default.
- W4283690952 hasConcept C147990577 @default.
- W4283690952 hasConcept C169760540 @default.
- W4283690952 hasConcept C170493617 @default.
- W4283690952 hasConcept C204232928 @default.
- W4283690952 hasConcept C2776214593 @default.
- W4283690952 hasConcept C2776263037 @default.
- W4283690952 hasConcept C2776997535 @default.
- W4283690952 hasConcept C2777433710 @default.
- W4283690952 hasConcept C2778857457 @default.
- W4283690952 hasConcept C2779959927 @default.
- W4283690952 hasConcept C71924100 @default.
- W4283690952 hasConcept C86803240 @default.
- W4283690952 hasConceptScore W4283690952C126322002 @default.
- W4283690952 hasConceptScore W4283690952C134018914 @default.
- W4283690952 hasConceptScore W4283690952C141071460 @default.
- W4283690952 hasConceptScore W4283690952C147990577 @default.
- W4283690952 hasConceptScore W4283690952C169760540 @default.
- W4283690952 hasConceptScore W4283690952C170493617 @default.
- W4283690952 hasConceptScore W4283690952C204232928 @default.
- W4283690952 hasConceptScore W4283690952C2776214593 @default.
- W4283690952 hasConceptScore W4283690952C2776263037 @default.
- W4283690952 hasConceptScore W4283690952C2776997535 @default.
- W4283690952 hasConceptScore W4283690952C2777433710 @default.
- W4283690952 hasConceptScore W4283690952C2778857457 @default.
- W4283690952 hasConceptScore W4283690952C2779959927 @default.
- W4283690952 hasConceptScore W4283690952C71924100 @default.
- W4283690952 hasConceptScore W4283690952C86803240 @default.
- W4283690952 hasIssue "Suppl 1" @default.
- W4283690952 hasLocation W42836909521 @default.
- W4283690952 hasOpenAccess W4283690952 @default.
- W4283690952 hasPrimaryLocation W42836909521 @default.
- W4283690952 hasRelatedWork W1995801352 @default.
- W4283690952 hasRelatedWork W2007723032 @default.
- W4283690952 hasRelatedWork W2029242893 @default.
- W4283690952 hasRelatedWork W2044505313 @default.
- W4283690952 hasRelatedWork W2057844010 @default.
- W4283690952 hasRelatedWork W2058701278 @default.
- W4283690952 hasRelatedWork W2922290759 @default.
- W4283690952 hasRelatedWork W3208848307 @default.
- W4283690952 hasRelatedWork W4283690952 @default.
- W4283690952 hasRelatedWork W4313410208 @default.
- W4283690952 hasVolume "81" @default.
- W4283690952 isParatext "false" @default.
- W4283690952 isRetracted "false" @default.
- W4283690952 workType "article" @default.